Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Three-Cohort Phase II Trial to Assess the Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Pleural or Malignant Peritoneal MESOthelioma Patients

NCT04462809 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT04462809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04462809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Three-Cohort Phase II Trial to Assess the Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Pleural or Malignant Peritoneal MESOthelioma Patients
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2020
Completion date
October 1, 2024
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant pleural or peritoneal mesothelioma